Artificial intelligence powered insulin technology, Diabeloop

Arathi Nair
Arathi Nair June 6, 2022
Updated 2022/06/23 at 3:26 PM
diabetes management

DBLG1 is a self-learning system that automates and customizes Type 1 diabetes treatment. The therapeutic artificial intelligence aims to relieve the psychological toll that comes with this chronic illness. People with diabetes now have access to technology that will virtually perform all of the work for them, after decades of juggling different gadgets and finger-prick systems to obtain their own blood glucose readings and use them to determine insulin dosages. This is called a hybrid closed-loop system.

diabeloop for diabetes

Existing commercial systems have algorithms built directly into their devices. Whereas Diabeloop’s DBLG1 algorithm is hosted on a dedicated app or receiver, which also serves as the user interface. It’s linked to an insulin pump and a continuous glucose monitor (CGM). Glucose measurement is sent to the handset every 5 minutes through Bluetooth technology. To decide the correct dosage of insulin to inject, the DBLG1 artificial intelligence analyses the data in real time, taking into account the patient’s history, physiology, and data entries (meals or exercise).

With two products on the European market and considerable developments with numerous device partners, Diabeloop has seen considerable growth in the last few years, nearing 10,000 equipped patients one year after commercial introduction.

Diabeloop has raised 70 million euros to fund its long-term expansion strategy. LBO Franceis, the prominent private equity player raised 70 million euros ($75 million). Terumo, a Diabeloop partner, as well as Innovacom, a Paris-based VC firm, and a few earlier investors in the startup, all contributed to the funding.

Diabeloop intends to use the funding to continue its AI-powered diabetes management system development, as well as to accelerate and expand the commercialization of its current technology around the world.

For quite some time, the firm has been preparing for its US debut. In 2020, it began a clinical trial of its core AI system. Last October, it formed a team in the United States to manage its FDA submissions and started carving out a market for Diabeloop’s technology in the United States.

For more such updates on smart homes, keep reading on techinnews.com

Share this Article